Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of “Hold” from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been assigned a consensus rating of “Hold” from the seven ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $4.25.

A number of analysts have recently issued reports on the company. Wall Street Zen cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings cut shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Oppenheimer restated an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th. Finally, HC Wainwright dropped their price objective on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a research note on Monday.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of hedge funds have recently made changes to their positions in INO. MCF Advisors LLC acquired a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at $26,000. SG Americas Securities LLC acquired a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at $27,000. Focus Partners Wealth acquired a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 5,894 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Inovio Pharmaceuticals by 752.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 18,160 shares during the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

NASDAQ:INO opened at $1.14 on Friday. The stock has a market cap of $93.79 million, a P/E ratio of -0.79 and a beta of 1.49. Inovio Pharmaceuticals has a one year low of $1.03 and a one year high of $2.98. The company has a fifty day moving average price of $1.27 and a 200 day moving average price of $1.61.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.02. As a group, equities research analysts anticipate that Inovio Pharmaceuticals will post -0.97 EPS for the current year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.